Ligand Pharmaceuticals Incorporated

LGND.US
Healthcare · Biotechnology
296.28
-1.22 (-0.41%)
USD · NASDAQ

Company Information

Company Name
Ligand Pharmaceuticals Incorporated
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US53220K5048
CIK: 0000886163
CUSIP: 53220K199
Currency: USD
Full Time Employees: 47
Phone: 858 550 7500
Fiscal Year End: December
IPO Date: Nov 18, 1992
Description:

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Address:

555 Heritage Drive, Jupiter, FL, United States, 33458

People

Directors & Officers

Name Title Year Born
Mr. Todd C. Davis Ph.D. CEO & Director 1961
Mr. Octavio Espinoza Chief Financial Officer 1971
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary 1975
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development NA
Ms. Melanie J. Herman CPA Executive Director of Investor Relations and Financial Planning & Analysis 1979

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 01, 2026 John W Kozarich N/A Sale 467.00 $202.23 $94.44K
Apr 01, 2026 Andrew Reardon N/A Sale 5.00K $201.24 $1.01M
Mar 23, 2026 Stephen L Sabba N/A Sale 1.00K $207.87 $207.87K
Mar 11, 2026 Octavio Espinoza N/A Sale 3.06K $225.00 $687.83K
Mar 04, 2026 Andrew Reardon N/A Sale 5.00K $206.35 $1.03M
Mar 04, 2026 Octavio Espinoza N/A Sale 13.42K $205.83 $2.76M
Mar 03, 2026 Stephen L Sabba N/A Sale 2.03K $201.50 $409.85K
Mar 03, 2026 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $204.24 N/A
Mar 02, 2026 John W Kozarich N/A Sale 467.00 $200.50 $93.63K
Feb 02, 2026 John W Kozarich N/A Sale 467.00 $195.91 $91.49K
Jan 15, 2026 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $196.08 N/A
Jan 05, 2026 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $192.03 N/A
Jan 02, 2026 John W Kozarich N/A Sale 467.00 $189.58 $88.53K
Dec 12, 2025 Octavio Espinoza N/A Sale 1.80K $188.31 $339.71K
Dec 01, 2025 John W Kozarich N/A Sale 467.00 $195.84 $91.46K
Nov 03, 2025 John W Kozarich N/A Sale 467.00 $191.05 $89.22K
Oct 01, 2025 John W Kozarich N/A Sale 467.00 $179.44 $83.80K
Sep 23, 2025 Jason Aryeh N/A Sale 10.00K $170.81 $1.71M
Sep 02, 2025 John W Kozarich N/A Sale 467.00 $162.26 $75.78K
Aug 01, 2025 John W Kozarich N/A Sale 467.00 $131.88 $61.59K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 2.96M Mar 31, 2026 14.78% $0.01 0.74%
Vanguard Group Inc 2.07M Dec 31, 2025 10.35% $0.01 -0.12%
Vanguard Portfolio Management, LLC 1.10M Mar 31, 2026 5.49% $0.01 0.00%
HHG PLC 1.01M Mar 31, 2026 5.04% $0.10 1.46%
Vanguard Capital Management, LLC 848.09K Mar 31, 2026 4.23% $0.00 0.00%
Amvescap Plc. 823.60K Mar 31, 2026 4.11% $0.02 59.47%
State Street Corp 778.86K Mar 31, 2026 3.89% $0.01 3.68%
Congress Asset Management Company, LLP 659.91K Jun 30, 2026 3.29% $1.28 30.77%
FMR Inc 596.13K Mar 31, 2026 2.97% $0.01 2.93%
Delaware Management Holdings Inc 573.31K Mar 31, 2026 2.86% $0.20 -10.99%
Franklin Resources Inc 573.18K Mar 31, 2026 2.86% $0.03 15.52%
Chicago Capital LLC 561.68K Mar 31, 2026 2.80% $3.02 0.04%
Geode Capital Management, LLC 558.93K Mar 31, 2026 2.79% $0.01 13.24%
Stephens Inv Mgmt Group LLC 494.67K Mar 31, 2026 2.47% $1.35 -1.27%
Dimensional Fund Advisors, Inc. 425.23K Mar 31, 2026 2.12% $0.02 -1.79%
Massachusetts Financial Services Company 411.54K Mar 31, 2026 2.05% $0.03 -18.83%
The Goldman Sachs Group Inc 381.11K Mar 31, 2026 1.90% $0.01 -11.16%
Loomis, Sayles & Company LP 353.21K Mar 31, 2026 1.76% $0.09 -7.70%
Deutsche Bank AG 306.11K Mar 31, 2026 1.53% $0.02 -0.57%
Victory Capital Management Inc. 303.22K Mar 31, 2026 1.51% $0.04 18.26%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 1.21M 6.03% ▲ 0.01% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 605.87K 3.02% ▲ 1.34% Jun 30, 2026
3 Franklin Innovation Composite 550.00K 2.74% ▲ 4.76% Jun 30, 2026
4 Franklin DynaTech Fund A 550.00K 2.74% ▲ 0.00% Jun 30, 2026
5 Invesco OFI Small Cap Growth 533.56K 2.66% ▲ 27.61% Jun 30, 2026
6 Invesco Discovery A 519.16K 2.59% ▲ 13.59% May 31, 2026
7 iShares Russell 2000 ETF 518.63K 2.59% ▲ 0.60% Jun 30, 2026
8 Janus Henderson US SMID Cap Growth 486.18K 2.43% ▼ 8.42% Mar 31, 2026
9 Janus Henderson Triton D 475.23K 2.37% ▼ 2.25% Apr 30, 2026
10 Vanguard Small Cap Index 436.66K 2.18% ▲ 1.55% Jun 30, 2026

Financial Highlights

Market Cap: $5.96B
EBITDA: $134.45M
P/E Ratio: $39.20
PEG Ratio: $1.53
Book Value: $49.79
Earnings/Share: $7.59
Profit Margin: 55.95%
Operating Margin: 33.58%
ROA (TTM): 5.19%
ROE (TTM): 17.13%
Revenue (TTM): $274.48M
Revenue/Share (TTM): $14.07
Earnings Growth (YOY): 103.20%
Revenue Growth (YOY): 14.10%

Valuation Metrics

Enterprise Value: $5.68B
Trailing P/E: 39.20
Forward P/E: 33.67

Shares Statistics

Shares Outstanding: 20.04M
Shares Float: 19.53M
% Insiders: 236.70%
% Institutions: 10,764.80%
Short % Float: 11.47%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$268.09M
Cost of Goods Sold
adjust
$-6.59M
Gross Profit
subtotal
$261.50M
SG&A
adjust
$-92.45M
R&D
adjust
$-81.18M
Other Operating Expense
adjust
$-40.67M
Operating Income
subtotal
$47.20M
Other / Non-Operating Items
adjust
$77.25M
Net Income
subtotal
$124.45M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about LGND.US!